Inventiva S.A. ADR (IVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IVA POWR Grades
- IVA scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.27% of US stocks.
- The strongest trend for IVA is in Momentum, which has been heading down over the past 26 weeks.
- IVA ranks lowest in Momentum; there it ranks in the 9th percentile.
IVA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IVA is 0.05 -- better than only 10.85% of US stocks.
- Inventiva SA's stock had its IPO on July 10, 2020, making it an older stock than only 0.39% of US equities in our set.
- With a price/sales ratio of 85.79, Inventiva SA has a higher such ratio than 96.25% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Inventiva SA, a group of peers worth examining would be MUX, VJET, TURN, OPGN, and ACOR.
- Visit IVA's SEC page to see the company's official filings. To visit the company's web site, go to www.inventivapharma.com.
IVA Stock Price Chart Interactive Chart >
IVA Price/Volume Stats
| Current price | $15.67 | 52-week high | $19.06 |
| Prev. close | $14.64 | 52-week low | $9.01 |
| Day low | $15.00 | Volume | 22,100 |
| Day high | $15.73 | Avg. volume | 27,636 |
| 50-day MA | $14.14 | Dividend yield | N/A |
| 200-day MA | $13.81 | Market Cap | 605.33M |
Inventiva S.A. ADR (IVA) Company Bio
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Latest IVA News From Around the Web
Below are the latest news stories about Inventiva SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast eventTwo oral presentations showing the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASHthe positive effects of lanifibranor on several biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis One poster presentation showing the beneficial effects of the combination treatment of lanifibranor and ACC1/2 inhibitor firsocostat from GileadInventiva will host a dedicated Key Opinion Leader (KOL) webcast event for investors and a |
Inventiva to participate at the Jefferies Virtual Healthcare ConferenceDaix (France), May 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company will participate to the upcoming Jefferies Virtual Healthcare Conference, being held virtually on June 1-4, 2021. During the event, members of the Company’s leadership will present a corporate overview, participate in a fireside chat and engage in 1x1 investor meetings. The event details are as follows: Date: Thursday, June 3, 2021Time: 9:00 am – 9:25 pm (ET) / 3:00 pm – 3:25 pm (CET)Participants: Frédéric Cren, Chairman, CEO and cofounder ... |
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseasesCash and cash equivalents at €107.8m as of March 31, 2021Revenues of €0.1m in Q1 2021Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial Daix (France), May 12, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of 2021, and provided an update on its collaboration with AbbVie in auto-immune diseases. Cash Position As of March 31, 2021, Inventiva’s cash and ... |
Inventiva to participate at the 7th Annual Truist Securities Life Sciences SummitDaix (France), April 26, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Inventiva will participate to the upcoming 7th Annual Truist Securities Life Sciences Summit, being held virtually on May 4-5, 2021. During the event, members of the Company’s leadership will engage in 1x1 investor meetings. The event details are as follows: Format: One-on-one investor meetingsParticipants: Frédéric Cren, Chairman, CEO and cofounder of Inventiva, and David Nikodem, Vice President of US Operations of InventivaDate: Tuesday-Wednesday, ... |
Point recommandations des analystes: LVMH Moet Vuitton, Quadient, Axa, CGG, Inventiva...https://www.tradingsat.com/actualites/avis-brokers/point-recommandations-des-analystes-lvmh-quadient-axa-cgg-inventiva-957177.html |
IVA Price Returns
| 1-mo | 10.35% |
| 3-mo | 22.42% |
| 6-mo | 30.58% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 8.07% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...